J&J unit, happy with AC Immune Alzheimer's work, moves 1 of 2 shots to next step

As the pharma world chatters about the merits of the amyloid theory in Alzheimer’s disease, Johnson & Johnson is taking things in another direction. The healthcare giant’s pharmaceutical unit Janssen has picked a tau vaccine from its collaboration with neurodegenerative-focused biotech AC Immune to advance into further development.